Nucleus, Science Highlights

Evaluating Allo-HCT for Myelodysplastic Syndromes in Young Adults

Jimenez AMJ, Eikema D-J, Koster L, et al. Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome in Young Adults: A Retrospective Study on Behalf of the EBMT Chronic Malignancies Working Party. Bone Marrow Transplantation. 2026; (doi; 10.1038/s41409-026-03036-3).

A retrospective analysis backs allogeneic hematopoietic cell transplantation (allo-HCT) in young adults with myelodysplastic syndromes (MDS), who are often missing from transplant study cohorts due to low incidence of the disease in their demographic. A search of European Society for Blood and Marrow Transplantation records from 2016 to 2021 yielded 697 MDS patients aged 18-40 years who underwent a first allo-HCT during that time span. At 3 years, the primary outcome of overall survival was 69%, while progression-free survival, a secondary endpoint, was 62%. Other 3-year results included a 20% cumulative incidence of relapse, non-relapse mortality of 18%, and an 18% rate of chronic and extensive chronic graft-versus-host disease. The research supports allo-HCT as an effective and curative intervention for young adults with MDS, although prospective studies are needed to support optimal timing, risk stratification, and transplant considerations like conditioning intensity and donor selection.

Read more.